Pulmocide Ltd

Pulmocide Limited develops biopharmaceutical therapies for respiratory diseases. The Company conducts clinical trials and advances novel inhaled antifungal compounds for targeted lung delivery. Pulmocide Ltd serves patients at risk of pulmonary aspergillosis in Europe, the United Kingdom, and the United States.